¼¼°èÀÇ ¾ÈÀü ÁÖ»ç±â ½ÃÀå
Safety Syringes
»óǰÄÚµå : 1744862
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 368 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,130,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,390,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¾ÈÀü ÁÖ»ç±â ½ÃÀåÀº 2030³â±îÁö 89¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 64¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ¾ÈÀü ÁÖ»ç±â ½ÃÀåÀº 2024-2030³â¿¡ CAGR 5.5%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 89¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ °³Æó½Ä ¾ÈÀü ÁÖ»ç±â´Â CAGR 6.5%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á±îÁö 59¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºñ°³Æó½Ä ¾ÈÀü ÁÖ»ç±â ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 3.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 18¾ï ´Þ·¯, Áß±¹Àº CAGR 8.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¾ÈÀü ÁÖ»ç±â ½ÃÀåÀº 2024³â¿¡ 18¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 18¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 8.9%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.6%¿Í 5.5%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ¾ÈÀü ÁÖ»ç±â ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

¾ÈÀüÁÖ»ç±â´Â ¼¼°è ÇコÄɾî Á¦°øÀÇ »õ·Î¿î »ó½Ä?

¾ÈÀü ÁÖ»ç±â ½ÃÀåÀº Áö³­ 10³â°£ Å« º¯È­¸¦ °ÞÀ¸¸ç Çö´ë ÀÇ·á ¾ÈÀü ÇÁ·ÎÅäÄÝÀÇ ÇÙ½ÉÀ¸·Î ºÎ»óÇß½À´Ï´Ù. ±âÁ¸ ÁÖ»ç±â¿Í ´Þ¸®, ¾ÈÀü ÁÖ»ç±â´Â ¿ì¹ßÀûÀÎ ¹Ù´Ã Âñ¸² »ç°í¿Í ±×¿¡ µû¸¥ HIV ¹× B/CÇü °£¿°°ú °°Àº Ç÷¾× ¸Å°³ º´¿øÃ¼ °¨¿°ÀÇ À§ÇèÀ» ¹æÁöÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ÁÖ»ç±â¿¡´Â Àç»ç¿ë ¹× ÁÖ»ç ÈÄ ¿ì¹ßÀû ³ëÃâÀ» ±â°èÀûÀ¸·Î ¹æÁöÇÏ´Â °³Æó½Ä, ÀÚµ¿°³Æó½Ä, ÇǺ¹½Ä µîÀÌ ÀÖ½À´Ï´Ù. ¼±Áø±¹°ú °³¹ßµµ»ó±¹À» ¸··ÐÇÏ°í º´¿ø, ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥, ÀçÅÃÄ¡·á ÇöÀå¿¡¼­µµ ÀÎ½Ä Áõ°¡, Á÷Àå ¾ÈÀü ±âÁØ °­È­, ±ÔÁ¦ °­È­·Î ÀÎÇØ ÀÌ·¯ÇÑ ±â±âÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, WHO, CDC ¹× °¢±¹ ÀÇ·á ±â°üÀº ¾ÈÀü ¼³°è ÁÖ»ç ½Ã½ºÅÛÀ¸·Î ÀüȯÀ» ÁöÁöÇÏ´Â ¸íÈ®ÇÑ °¡À̵å¶óÀÎÀ» ¹ßÇ¥Çß½À´Ï´Ù. °¡À̵å¶óÀÎÀ» ¹ßÇ¥Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ COVID-19 ÆÒµ¥¹Í ÀÌÈÄ Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ Á¢±Ù¼ºÀ» ³ôÀÌ°í ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ÀÇ ±Ô¸ð¸¦ È®´ëÇÔ¿¡ µû¶ó ¾ÈÀü ÁÖ»ç±â´Â ¸ðµç Ä¡·á ½ÃÁ¡¿¡¼­ ¼±ÅûçÇ׿¡¼­ Çʼö»çÇ×À¸·Î ÀüȯµÇ°í ÀÖ½À´Ï´Ù.

±â¼ú Çõ½Å°ú ±ÔÁ¦´Â Á¦Ç°ÀÇ ÁøÈ­¸¦ ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

¾ÈÀü ÁÖ»ç±âÀÇ ±â¼ú Çõ½ÅÀº ¼º´É°ú »ç¿ë ÆíÀǼºÀ» ºü¸£°Ô Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÆÐ½Ãºê ¾ÈÀü ¸ÞÄ¿´ÏÁòÀ» °®Ãá Â÷¼¼´ë °³Æó½Ä ÁÖ»ç±â´Â »ç¿ëÀÚÀÇ °³ÀÔÀ» ÁÙ¿©ÁÖ¸ç, ƯÈ÷ ´ë·® ¹é½Å Á¢Á¾ Ä·ÆäÀο¡¼­ À¯¿ëÇÕ´Ï´Ù. FDA, EMA, °¢±¹ Á¤ºÎ ºÎóÀÇ ±ÔÁ¦ ¾Ð·ÂÀ¸·Î ÀÎÇØ Á¦Á¶¾÷ü´Â ISO 23908 ¹× ±âŸ ¾ÈÀü Ç¥ÁØÀ» ÁؼöÇØ¾ß ÇÑ´Ù´Â ¾Ð¹ÚÀ» ¹Þ°í ÀÖÀ¸¸ç, ÀϹæÇâ Ç÷±Àú¿Í º¯Á¶ ¹æÁö ¼³°è¸¦ ÅëÇØ Àç»ç¿ëÀ» ¹æÁöÇÒ ¼ö ÀÖ´Â ÀÚµ¿ ºñȰ¼ºÈ­ ¸ðµ¨À» °³¹ßÇß½À´Ï´Ù. ¶ÇÇÑ À¯´Ï¼¼ÇÁ¿Í GAVI¿Í °°Àº Á¶´Þ ±â°üÀº WHOÀÇ PQS(¼º´É, ǰÁú, ¾ÈÀü¼º) ÀÎÁõÀ» ¹ÞÀº ¾ÈÀü ÁÖ»ç±â¸¦ Á¦°øÇÏ´Â °ø±Þ¾÷ü¿¡ ¿ì¼±±ÇÀ» ºÎ¿©Çϰí ÀÖ½À´Ï´Ù. Á¦Á¶¾÷üµéÀº ¶ÇÇÑ ¹é½ÅÀÇ ³¶ºñ¸¦ ÃÖ¼ÒÈ­ÇÏ°í ´Ù¾çÇÑ »ý¹°Á¦Á¦¿Í ȣȯµÇ´Â ÀÏȸ¿ë, ³·Àº µ¥µå½ºÆäÀ̽º ¼³°è¸¦ ÅëÇØ ºñ¿ë È¿À²¼ºÀ» ÃÖÀûÈ­Çϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ±â¼ú Çõ½Å°ú ¼¼°è ½ÃÀå ħÅõ¸¦ °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ö¿ä¸¦ ÁÖµµÇÏ´Â ÁÖ¿ä ÃÖÁ¾»ç¿ëÀÚ µ¿ÇâÀº?

¸¸¼ºÁúȯ Ä¡·á¿Í ÀçÅÃÀÇ·á Áõ°¡´Â ¾ÈÀü ÁÖ»ç±â º¸±Þ¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ´ç´¢º´ ȯÀÚµéÀº º¸´Ù »ç¿ëÇϱ⠽±°í ¾ÈÀüÇÑ Àν¶¸° Åõ¿© ÅøÀ» Á¡Á¡ ´õ ¸¹ÀÌ ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. º´¿ø°ú ¿Ü·¡ Áø·á¼Ò¿¡¼­´Â ȯÀÚÀÇ ¾ÈÀü»Ó¸¸ ¾Æ´Ï¶ó Á÷¿øÀÇ º¹¸®ÈÄ»ýÀ» ¿ì¼±½ÃÇϰí ÀÖÀ¸¸ç, »ê¾÷ º¸°Ç »ç°í¸¦ ÁÙÀ̱â À§ÇØ ¾ÈÀü ¼³°èµÈ ÀåºñÀÇ »ç¿ëÀÌ Àǹ«È­µÇ¾î ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î µ¶°¨, HPV, COVID-19 µîÀ» ´ë»óÀ¸·Î ÇÏ´Â Áý´Ü ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥¿¡¼­´Â ½Å¼ÓÇϰí À§»ýÀûÀÎ ¹èÄ¡¸¦ º¸ÀåÇϱâ À§ÇØ ¾ÈÀü ÁÖ»ç±â°¡ Áß¿äÇÏ°Ô È°¿ëµÇ°í ÀÖ½À´Ï´Ù. ½ÅÈï °æÁ¦ ±¹°¡µéÀº ¼¼°èº¸°Ç±â±ÝÀÇ Áö¿øÀ» ¹Þ¾Æ ¾ÈÀü ÁÖ»ç±â¸¦ ±¹°¡ Á¶´Þ Ç¥ÁØ¿¡ Æ÷ÇÔ½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼ÒºñÀÚ ±³À° ¹× ÀÇ·á Á¾»çÀÚ ¾ÈÀüÀ» ´Ù·ç´Â ¹ýÀû ÇÁ·¹ÀÓ¿öÅ©´Â ±Þ¼º±â ¹× ¿Ü·¡ ÀÇ·á ¸ðµÎ¿¡¼­ »çÀü ÃæÀüµÈ ¾ÈÀü ÁÖ»ç±âÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÃÖÁ¾ ¿ëµµ µ¿ÇâÀº ¸ðµÎ ÁÖ»çÁ¦ Ç¥ÁØÀÌ Àü ¼¼°è¿¡¼­ ¿µ±¸ÀûÀ¸·Î º¯È­Çϰí ÀÖÀ½À» º¸¿©ÁÝ´Ï´Ù.

¾ÈÀü ÁÖ»ç±â ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀÎÀ¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù.

¾ÈÀü ÁÖ»ç±â ½ÃÀåÀÇ ¼ºÀåÀº Àü ¼¼°è ¹é½Å Á¢Á¾ Áõ°¡, ÁÖ»ç ¿ä¹ýÀ» ÇÊ¿ä·Î ÇÏ´Â ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡, ¾ÈÀüÇÑ ÁÖ»ç °üÇàÀ» ÃËÁøÇÏ´Â ¾ö°ÝÇÑ ±ÔÁ¦ ½ÃÇàÀ¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ÀÇ·á Á¾»çÀÚ Áõ°¡¿Í º´¿ø³» °¨¿°¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÓ»ó ÇöÀå¿¡¼­ ¾ÈÀü ÀåºñÀÇ »ç¿ëÀÌ Àǹ«È­µÇ¾ú½À´Ï´Ù. ÅëÇÕÇü ¼ö³³Çü µðÀÚÀÎ, µ¥µå½ºÆäÀ̽º°¡ ÀûÀº À¯Çü µî ±â¼úÀÇ ¹ßÀüÀ¸·Î ÄÄÇöóÀ̾𽺸¦ °³¼±ÇÏ°í ³¶ºñ¸¦ ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÚ°¡ ÁÖ»ç ¹× ÀçÅà ġ·á¿¡ ´ëÇÑ ¼ÒºñÀÚ ÇൿÀÇ º¯È­´Â Á÷°üÀûÀÌ°í »ç¿ëÇϱ⠽¬¿î ¾ÈÀü ÁÖ»ç±â¿¡ ´ëÇÑ ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±¹Á¦ÀûÀÎ ÀÚ±Ý Áö¿ø ±â°ü°ú ºñ¿µ¸® ´ÜüÀÇ Áö¿øÀ¸·Î ÁßÀú¼Òµæ ±¹°¡¿¡¼­ÀÇ Ã¤ÅÃÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. °ø±Þ¸Á Çõ½Å°ú °³ÀÎ ºê·£µå »ý»êÀº ƯÈ÷ ´ë·® ÀÔÂû¿¡¼­ ÀÌ·¯ÇÑ ÀåºñÀÇ °¡°ÝÀ» ´õ¿í Àú·ÅÇÏ°Ô ¸¸µé°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼µéÀ» Á¾ÇÕÇϸé Àü ¼¼°è ÀÇ·á »ýŰè Àü¹Ý¿¡ °ÉÃÄ ÁÖ»çÁ¦ ¾ÈÀüÀÌ À籸¼ºµÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(°³Æó½Ä ¾ÈÀü ÁÖ»ç±â, ºñ°³Æó½Ä ¾ÈÀü ÁÖ»ç±â), À¯Çü(ÀåÂø½Ä ¹Ù´Ã, Å»Âø½Ä ¹Ù´Ã), ÃÖÁ¾ ¿ëµµ(º´¿ø, ÇåÇ÷ Ä·ÇÁ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÃÑ 41°Ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»±¹, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÔ¿ø°¡ Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ < gt; Áß±¹ < gt; ¸ß½ÃÄÚ < gt; ij³ª´Ù < gt; EU < gt; ÀϺ» < gt; Àεµ < gt; ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Safety Syringes Market to Reach US$8.9 Billion by 2030

The global market for Safety Syringes estimated at US$6.4 Billion in the year 2024, is expected to reach US$8.9 Billion by 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. Retractable Safety Syringes, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$5.9 Billion by the end of the analysis period. Growth in the Non Retractable Safety Syringes segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 8.9% CAGR

The Safety Syringes market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 8.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Safety Syringes Market - Key Trends & Drivers Summarized

Are Safety Syringes the New Norm in Global Healthcare Delivery?

The safety syringes market has undergone a major transformation in the last decade, emerging as a cornerstone of modern medical safety protocols. Unlike traditional syringes, safety syringes are designed to prevent accidental needlestick injuries and the associated risk of transmitting bloodborne pathogens such as HIV and hepatitis B/C. These syringes include retractable, auto-disable, and sheathing varieties that mechanically prevent reuse or accidental exposure post-injection. Hospitals, vaccination programs, and even home-care settings are increasingly adopting these devices due to rising awareness, stringent workplace safety standards, and regulatory mandates across both developed and developing regions. The WHO, CDC, and national healthcare bodies have issued clear guidelines supporting the shift toward safety-engineered injection systems. As the global healthcare system expands access and scales up immunization programs-especially after the COVID-19 pandemic-safety syringes are moving from optional to essential across all points of care.

How Are Innovation and Regulation Shaping Product Evolution?

Technological innovation in safety syringes is rapidly improving both performance and user-friendliness. Next-generation retractable syringes with passive safety mechanisms reduce user intervention, making them especially useful during high-volume vaccination campaigns. Advanced auto-disable models prevent reuse through one-way plungers or tamper-evident designs, which are critical in regions prone to equipment misuse. Regulatory pressure from bodies like the FDA, EMA, and national ministries is pushing manufacturers to conform to ISO 23908 and other safety standards. Furthermore, procurement agencies such as UNICEF and GAVI are prioritizing suppliers offering WHO PQS (Performance, Quality, and Safety)-certified safety syringes. Manufacturers are also optimizing for cost efficiency, with disposable low-dead space designs that minimize vaccine wastage and are compatible with a wide range of biologicals. These trends are accelerating both innovation and global market penetration.

What Are the Key End-User Trends Driving Market Demand?

The rise in chronic disease treatment and home-based care is contributing significantly to the uptake of safety syringes. Diabetic patients, for instance, increasingly demand user-friendly, safer insulin administration tools. Hospitals and outpatient clinics are now prioritizing not just patient safety but also staff welfare, mandating safety-engineered devices to reduce occupational health incidents. Similarly, mass immunization programs-such as those targeting influenza, HPV, or COVID-19-rely heavily on safety syringes to ensure rapid and hygienic deployment. Developing economies, backed by global health funding, are integrating safety syringes into national procurement standards. Additionally, consumer education and legal frameworks addressing healthcare worker safety are driving the adoption of prefilled safety syringes in both acute care and ambulatory settings. All these end-use trends point toward a permanent global shift in injection standards.

The Growth in the Safety Syringes Market Is Driven by Several Factors

Growth in the safety syringes market is driven by increasing global vaccination efforts, rising incidence of chronic diseases requiring injectable therapies, and stringent regulatory enforcement promoting safe injection practices. A growing healthcare workforce and rising hospital-acquired infection awareness have prompted mandatory use of safety devices in clinical settings. Technological advancements-including integrated retractable designs and low-dead space variants-are improving compliance and minimizing waste. Changing consumer behavior toward self-injection and home treatment has created demand for intuitive, easy-to-use safety syringes. Further, support from international funding agencies and non-profits is accelerating adoption in low- and middle-income countries. Supply chain innovations and private-label production are making these devices more affordable, especially in bulk tenders. Collectively, these trends are reshaping injection safety across the global medical ecosystem.

SCOPE OF STUDY:

The report analyzes the Safety Syringes market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Retractable Safety Syringes, Non Retractable Safety Syringes); Type (Attached Needle, Detachable Needles); End-Use (Hospitals, Blood Donation Camps, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â